These people are cautious and even prohibit taking cabozantinib

In addition to treating advanced liver cancer, kidney cancer and thyroid cancer, cabozantinib also has a good effect on soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer and colon cancer. Although Cabozantinib is suitable for the treatment of advanced liver cancer, kidney cancer and thyroid cancer, not all patients with these diseases can take it. The following special groups need to be cautious, and even prohibit taking cabozantinib!

Pregnant women, breastfeeding women, women with reproductive potential, men, children, the elderly, and patients with impaired liver function should be cautious when taking or banning cabozantinib.

1. Pregnant women are prohibited from taking cabozantinib.
   Pregnant women taking cabozantinib may cause harm to the fetus. Although there is no relevant clinical data on pregnant women to explain the harm of Cabozantinib to pregnant women, it was found in the animal development and reproductive toxicology studies of Cabozantinib that pregnant rats and rabbits took Cabozant during pregnancy. Nicolas can cause embryonic death and structural abnormalities. Therefore, it is recommended that pregnant women or women of childbearing age have potential risks to the fetus.
2. Breastfeeding women should be cautious when taking cabozantinib.
   There is no information on the presence of cabozantinib or its metabolites in breast milk and its effect on breastfed infants or milk production. However, we cannot worry about the possible serious adverse effects on breastfed infants of breastfed women taking Cabozantinib. Therefore, breastfeeding women should be advised not to take cabozantinib during treatment with cabozantinib and within 4 months after the last breastfeeding.
3. Women and men with reproductive potential should be cautious in taking cabozantinib.
   Women and men of reproductive potential taking cabozantinib may harm their fertility. If they become pregnant while taking it, it may cause harm to the fetus. Therefore, it is recommended that women with reproductive potential use effective contraception during treatment with cabozantinib and for 4 months after the final dose, and men with reproductive potential should also pay attention to effective contraception.
4. Children and the elderly should be cautious when taking cabozantinib.
   At present, the safety and effectiveness of cabozantinib have not been found in studies in children and elderly patients. However, children are in the stage of growth and development. Taking the anti-cancer drug Cabotinib at a young age will definitely affect the growth and development of children. In addition to advanced liver cancer, most elderly patients have other basic diseases, such as high blood pressure or heart disease. Be careful when taking cabozantinib, because cabozantinib can affect the development of underlying diseases, such as high blood pressure or heart disease. Therefore, children and the elderly should be cautious when taking cabozantinib.
5. Patients with impaired liver function should be cautious when taking cabozantinib.
   According to relevant clinical studies, it has been found that increased exposure to cabozantinib has been observed in patients with mild to moderate hepatic impairment. Therefore, patients with mild to moderate liver damage should reduce the dose of cabozantinib, while patients with severe liver damage should not take cabozantinib.